Paradoxical Response Developed during the Antituberculous Treatment in Tuberculous Pleurisy. |
Eun Ju Song, Dae Hyun Baek, Jun Young Jung, Sang Ryul Lee, Myong Ha Lee, Sung Hyuk Lee, Jae Hyung Lee, Ki Deok Lee, Byoung Hoon Lee, Sang Hoon Kim |
Department of Internal Medicine, Eulji Hospital, College of Medicine, Eulji University, Seoul, Korea. hoonakr@eulji.ac.kr |
|
Abstract |
BACKGROUND A paradoxical response is defined as the radiological and clinical worsening of a previous lesion or the development of new lesion after initial improvement during theprocess of antituberculous treatment. The related factors for the development of a paradoxical response in patients with tuberculous pleurisy are not certain. METHODS: We selected patients with tuberculous pleurisy who had been treated for more than 4 months. The changes onthe serial chest X-ray findings before and after treatment were reviewed. Paradoxical responses were regarded as any worsening or development of new lesion at least 2 weeks after the initiation of treatment. The baseline clinical characteristics and laboratory findings of the peripheral blood and pleural fluid were compared between the patients with a paradoxical response and the patients without a paradoxical response. RESULTS: Paradoxical responses appeared in sixteen patients (21%) among the 77 patients.It took a mean of 38.6 days after the treatment and the time to resolve the paradoxical response was a mean of 32.1 days. For the patients with a paradoxical response, the median age was younger (30.5 years vs 39.0 years, respectively) and the lymphocytic percentage of white blood cells in the pleural fluid was higher (82.1% vs 69.6%, respectively) than for the patients without a paradoxical response. CONCLUSION: The development of a paradoxical response during the treatment of patients with tuberculous pleurisy was not rare and this was related with the age of the patients and the percentage of lymphocytic white blood cells in the pleural fluid. |
Key Words:
Tuberculous pleurisy, Paradoxical response, Antitubercular agents |
|